Skip to content

Tesamorelin

An FDA-approved GHRH analog used to reduce visceral fat in HIV-associated lipodystrophy.

AStrongWell-Studied
Last updated 31 citations

What is Tesamorelin?

Tesamorelin is a synthetic GHRH analog that is currently FDA-approved (brand name Egrifta) for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy. It is one of the few peptides in this space with full FDA approval for a therapeutic indication, which provides a stronger evidence base than most other peptides discussed for body composition.

What Tesamorelin Is Investigated For

Tesamorelin is investigated and FDA-approved for reducing excess abdominal fat in HIV-infected patients with lipodystrophy, and the strongest evidence — a full Phase 3 program published by Falutz and colleagues — established roughly 15–18% visceral fat reduction at 26 weeks, extended to 52 weeks with sustained benefit. It is the only GHRH analog currently holding FDA approval, which places it in a different regulatory and evidence tier from CJC-1295 or modified GRF(1-29). Off-label interest centers on adult body composition, cognitive function (with a small Baker et al. mild cognitive impairment trial), and non-HIV NAFLD. The honest caveats are important: the approved evidence base is specific to HIV-lipodystrophy, dedicated RCTs of tesamorelin in healthy aging adults for longevity or body-composition goals do not exist, visceral fat regresses when treatment stops (the benefit is chronic-treatment-dependent, not one-time remodeling), and tesamorelin is explicitly prohibited under WADA's S2 category regardless of its FDA-approved status. Glucose and HbA1c monitoring is built into the label because GH elevation worsens glycemic control.

Visceral fat reduction
Strong90%
Growth hormone optimization
Strong90%
Body composition improvement
Moderate70%
Cognitive function (emerging research)
Preliminary30%

History & Discovery

Tesamorelin was developed by Theratechnologies, a Montreal-based biopharmaceutical company, and represents an unusual case in the peptide landscape: a GHRH analog that successfully completed the full regulatory pathway and reached FDA approval. The compound is a synthetic analog of human growth hormone-releasing hormone, GHRH(1-44), with a single N-terminal modification — a trans-3-hexenoyl group attached to the tyrosine at position 1 — that dramatically reduces proteolytic degradation and extends in vivo activity compared to native GHRH. The underlying GHRH structure was characterized at the Salk Institute in the 1980s by Roger Guillemin's group; Theratechnologies' contribution was the stabilizing modification and the completion of the clinical development program. The development program targeted HIV-associated lipodystrophy, a treatment-related condition in which antiretroviral therapy causes excess visceral fat accumulation along with peripheral lipoatrophy. The Phase III program, published by Falutz, Mamputu, and colleagues between 2007 and 2010, demonstrated significant visceral adipose tissue reduction measured by CT scan, with concurrent improvements in lipid profile and adiponectin. The FDA approved tesamorelin as Egrifta in November 2010 for reduction of excess abdominal fat in HIV-infected patients with lipodystrophy, and Health Canada approval followed. Tesamorelin remains the only GHRH analog with current FDA approval — sermorelin (the shorter GHRH(1-29) fragment) had a prior approval that was withdrawn in 2008, and all other GHRH analogs discussed in wellness contexts (CJC-1295, modified GRF 1-29) remain unapproved investigational compounds. More recently, Theratechnologies reformulated the product as Egrifta SV (single-vial, the F1 formulation retaining the 2 mg daily dose) and Egrifta WR (F8 formulation approved by the FDA on March 25, 2025, with commercial launch on September 5, 2025) — the WR variant uses weekly rather than daily reconstitution and delivers a lower 1.28 mg daily dose (0.16 mL from an 11.6 mg vial supplying a 7-day reconstituted course), bioequivalent to F1 with about half the injection volume. In September 2025 Theratechnologies was acquired by Future Pak / CB Biotechnology following a definitive agreement announced in July 2025, with commercialization of the Egrifta franchise now passing to the new owner. The compound has also been studied off-label for cognitive endpoints (Baker and colleagues, mild cognitive impairment) and for non-HIV NAFLD.

How It Works

Tesamorelin works the same way as your body's natural growth hormone-releasing hormone, but with modifications that make it more potent and longer-lasting. It tells your pituitary gland to release more growth hormone, which in turn helps reduce visceral (deep belly) fat.

Tesamorelin is a synthetic analog of human GHRH(1-44) with a trans-3-hexenoic acid modification at the N-terminus that enhances receptor binding affinity and resistance to enzymatic degradation. It binds to pituitary GHRH receptors, stimulating GH synthesis and secretion. Clinical trials have demonstrated significant reductions in visceral adipose tissue (VAT) as measured by CT scan, along with improvements in trunk fat and lipid profiles.

Evidence Snapshot

Overall Confidence90%

Human Clinical Evidence

Very strong. Multiple Phase III randomized controlled trials. FDA-approved based on rigorous clinical evidence.

Animal / Preclinical

Strong. Comprehensive preclinical development program.

Mechanistic Rationale

Very strong. Well-characterized GHRH receptor agonism.

Research Gaps & Open Questions

What the current literature has not yet settled about Tesamorelin:

  • 01Long-term (>2 year) safety data outside the HIV-lipodystrophy population is limited; the pivotal program's extension data extends to roughly 52 weeks, and chronic multi-year use in non-HIV populations is less well-characterized than the approved indication suggests on first reading. A mandated 10-year post-marketing cohort study is tracking malignancy, type 2 diabetes, retinopathy, and major adverse cardiovascular events in HIV-lipodystrophy patients on tesamorelin — this is the primary source of emerging chronic-use safety data but has not yet fully reported.
  • 02Efficacy and safety of tesamorelin specifically in healthy aging adults pursuing body-composition or longevity goals — the dominant off-label use case — has not been tested in dedicated RCTs. The cognitive-impairment trial by Baker and colleagues is an exception but remains small.
  • 03Tesamorelin's effect on cardiovascular endpoints (MACE, heart failure, arrhythmia) over years of continuous use has not been directly characterized in a dedicated endpoint trial; available data is limited to metabolic-marker improvements.
  • 04Whether tesamorelin's favorable outcomes in NAFLD translate to hard liver endpoints (fibrosis progression, hepatocellular carcinoma incidence) in populations without HIV coinfection has not been established.
  • 05Comparative effectiveness data against newer GHRH analogs and against non-GHRH weight-management therapies (particularly GLP-1 receptor agonists) for visceral fat reduction in non-HIV populations is sparse.
  • 06Durability of benefit after discontinuation has been characterized in HIV-lipodystrophy but not in other off-label populations; the regression-after-discontinuation finding is meaningful for patient counseling about long-term commitment.

Forms & Administration

Tesamorelin is administered via subcutaneous injection. As an FDA-approved medication, it has specific prescribing information and dosing guidelines available. All injectable peptides should only be administered under the guidance of a qualified healthcare provider. Never self-administer without clinician oversight.

Dosing & Protocols

The ranges below reflect protocols commonly discussed in the literature and by clinicians — not a prescription. Actual dosing for any individual should be determined by a qualified healthcare provider who knows the patient.

Typical Range

The FDA-approved adult dose of tesamorelin for HIV-associated lipodystrophy is 2 mg subcutaneously once daily using Egrifta SV (F1 formulation) — the dose established across the Phase III program. Egrifta WR (F8 formulation, FDA-approved March 25, 2025; commercial September 5, 2025) is bioequivalent but delivers a lower 1.28 mg daily dose (0.16 mL from an 11.6 mg vial reconstituted weekly), reflecting the reformulation rather than a reduced clinical target. Off-label protocols in the wellness and longevity space largely mirror the daily dose of whichever formulation is prescribed. Dose reduction below labeled levels is not typically discussed because sub-therapeutic dosing is unlikely to reproduce the clinical-trial body-composition effects.

Frequency

Tesamorelin is dosed once daily via subcutaneous injection. Its short pharmacokinetic half-life (plasma clearance within hours) is balanced by its persistent ability to stimulate pulsatile GH release; daily dosing produces sustained IGF-1 elevation. The labeled administration time is consistent across doses, with morning or evening administration both acceptable. Unlike shorter-acting GHRH peptides that are sometimes dosed multiple times per day, tesamorelin's potency and stability make once-daily the standard.

Timing Considerations

Time of day

Evening or bedtime injection is the standard protocol, matching both the natural nocturnal GH pulse and the regimen used in the HIV-lipodystrophy approval trials.

Relative to meals

Fasted is preferable for maximum GH response — at least 30 minutes before food and a few hours after a meal — though tesamorelin's GHRH-receptor mechanism is less meal-sensitive than ghrelin-mimetics like ipamorelin or GHRP-6.

Relative to exercise

Not tied to training.

Cycle Length

The approved indication supports continuous daily use. Theratechnologies' long-term extension data (published by Falutz and colleagues) support continued use beyond 26 weeks with sustained visceral-fat reduction and a reasonable safety profile in the HIV-lipodystrophy population. The FDA label does not specify a maximum duration. In off-label wellness use, practitioners sometimes cycle tesamorelin in 3–6 month blocks with breaks, though this pattern is a generic GH-secretagogue convention rather than a tesamorelin-specific evidence-based practice. Published efficacy is tied to continued dosing: the visceral-fat reduction regresses when treatment is stopped.

Protocol Notes

Tesamorelin is supplied as a lyophilized powder in vials, reconstituted with supplied sterile water for injection per the product labeling. Egrifta SV (F1) is reconstituted daily; Egrifta WR (F8, approved March 2025) is reconstituted once and the reconstituted solution is drawn from across a 7-day course, reducing the daily handling burden and cutting injection volume by roughly half. Subcutaneous injection into the abdomen is the standard route for both formulations, with site rotation between abdominal quadrants to reduce injection-site reaction and avoid localized lipoatrophy or lipohypertrophy — particularly relevant given the lipodystrophy patient population. Injection timing is not meal-dependent in the same way ghrelin-receptor agonists are, because tesamorelin acts at the GHRH receptor rather than the ghrelin receptor, and the GH-releasing effect is not blunted by recent food intake to the same degree. Monitoring of IGF-1 levels, glucose, and HbA1c is standard during treatment. The approved product comes with formal prescribing information; this site is not a substitute for that document.

Tesamorelin is FDA-approved only for reduction of excess abdominal fat in HIV-infected patients with lipodystrophy. All other uses — general wellness, longevity, non-HIV body composition, cognitive enhancement — are off-label. Off-label use should be undertaken only under qualified clinician supervision with appropriate monitoring.

Timeline of Effects

Onset

Serum IGF-1 elevation is measurable within days of starting daily dosing, with a substantial rise typically evident by the end of the first week. Subjective effects — improved sleep quality, modest early recovery benefits — often appear in the first 2–4 weeks. The indication-defining outcome, visceral adipose tissue reduction, is not measurable until weeks of consistent dosing; the Phase III trials reported statistically significant VAT reduction at the 26-week primary endpoint, with effect sizes building progressively through the dosing period.

Peak Effect

Visceral fat reduction in the Phase III program reached roughly 15–18% at 26 weeks of daily dosing and continued to accumulate modestly through 52 weeks in extension studies. IGF-1 elevation reaches a near-plateau within the first month and is sustained as long as daily dosing continues. Subjective body-composition, skin-quality, and sleep benefits reported in off-label wellness use most commonly plateau around 3–6 months, which aligns with the trial trajectory.

After Discontinuation

Because tesamorelin does not suppress endogenous GHRH — it augments the signal rather than replacing pituitary function — endogenous pulsatile GH secretion returns to baseline within days to weeks of discontinuation. IGF-1 drifts back to pre-treatment levels over 2–4 weeks. Crucially, the visceral-fat reduction achieved during treatment is not durable: the Phase III program demonstrated that patients who stopped tesamorelin after 26 weeks regained visceral fat over the subsequent months, while those who continued dosing maintained or further reduced VAT. This is a defining feature of the therapy — the effect is treatment-dependent, not a one-time remodeling.

Monitoring & Measurement

Bloodwork & Labs

  • IGF-1 (serum) — expect a 40–70% rise by week 12
  • Fasting glucose and HbA1c — tesamorelin trials showed modest fasting-glucose rises; worth early checks in anyone insulin-resistant at baseline
  • Lipid panel — visceral-fat reduction typically drives triglyceride drops
  • ALT and AST — VAT and hepatic fat correlate, so liver enzymes are a relevant adjacent marker

Functional & Performance Tests

  • Waist circumference — the cheap, reliable visceral-fat proxy
  • DEXA scan with VAT segment — the closest at-home gold standard
  • Abdominal MRI or MRI-PDFF for NAFLD-focused users with access — the trial gold standard for both VAT and liver fat

When to Test

Baseline, 12 weeks, and 26 weeks — the 26-week mark mirrors the approval trial endpoint.

Interpretation & Notes

Tesamorelin's flagship outcome is roughly a 15–18% visceral adipose tissue reduction at 26 weeks. Abdominal MRI is the clinical gold standard for VAT measurement, but DEXA with VAT estimation and tape-measured waist circumference are reasonable proxies for most users. IGF-1 typically rises 40–70% — if yours doesn't move by week 12 at a therapeutic dose, investigate adherence and source quality before assuming non-response. Unlike ipamorelin and CJC-1295, tesamorelin has robust RCT data behind it, so the response distribution is well-characterized; deviations from expected trajectory are more interpretable. Panels are direct-to-consumer; imaging typically requires a clinician order.

Common Questions

Who Tesamorelin Is NOT For

Contraindications
  • Active malignancy — the FDA label explicitly contraindicates tesamorelin in patients with active malignancy, because sustained GH and IGF-1 elevation may accelerate proliferation of existing tumors. Patients with a prior history of cancer require careful individual evaluation; the label advises against initiating treatment in patients with active disease.
  • Disrupted hypothalamic-pituitary axis from hypophysectomy, hypopituitarism, pituitary tumor or surgery, head irradiation, or head trauma — tesamorelin requires an intact somatotroph axis to be pharmacologically useful, and its use is contraindicated in patients without one.
  • Pregnancy — tesamorelin is contraindicated in pregnancy per the approved label; the GH/IGF-1 axis changes substantially during pregnancy and the pharmacologic effects have not been characterized in reproductive-toxicology frameworks adequate to support use.
  • Known hypersensitivity to tesamorelin or mannitol (a formulation excipient) — serious hypersensitivity reactions including anaphylaxis have been reported.
  • Diabetes or impaired glucose tolerance — tesamorelin is not absolutely contraindicated in diabetes, but it can worsen glycemic control and the approved label requires glucose and HbA1c monitoring. In patients with poorly controlled diabetes, the risk-benefit calculation frequently argues against use.
  • Pediatric use — tesamorelin is not approved for use in pediatric patients, and long-bone growth considerations would require specialist oversight if considered.

Drug & Supplement Interactions

Tesamorelin has a more developed drug-interaction profile than most peptides in this space because of its FDA approval, though the human dataset remains modest. The prescribing information and published literature describe several meaningful interactions. Glucose-regulating medications — insulin, sulfonylureas, GLP-1 receptor agonists — interact with GH's counter-regulatory effect on glucose. Tesamorelin-treated patients frequently require dose adjustment of antidiabetic agents as IGF-1 rises and insulin sensitivity shifts; glucose and HbA1c monitoring is built into the approved prescribing information for exactly this reason. Corticosteroids (prednisone, dexamethasone) blunt GH secretion at the pituitary level and can attenuate tesamorelin's clinical effect; in the HIV-lipodystrophy population, concurrent corticosteroid use is a recognized consideration. In the HIV-treatment context, CYP3A4-metabolized drugs warrant attention: GH elevation can alter hepatic enzyme activity, and several antiretroviral agents are CYP3A4 substrates. Thyroid hormone status matters — hypothyroidism blunts GH response, and uncorrected thyroid dysfunction should be addressed first. Estrogens modulate GH/IGF-1 coupling, with oral estrogens in particular reducing hepatic IGF-1 generation, which affects interpretation of monitoring labs. Somatostatin analogs (octreotide, lanreotide) directly oppose GHRH signaling and will pharmacologically antagonize tesamorelin. Patients on any regular medication should discuss tesamorelin with their prescribing clinician.

Safety Profile

Safety Information

Common Side Effects

Injection site reactionsJoint painPeripheral edemaParesthesia

Cautions

  • FDA-approved only for HIV lipodystrophy
  • Contraindicated in pregnancy
  • Monitor IGF-1 levels
  • Discontinue if hypersensitivity occurs

What We Don't Know

Long-term effects beyond the studied HIV lipodystrophy population are less characterized for off-label applications.

Myths & Misconceptions

Myth

Tesamorelin is the same thing as CJC-1295 because both are GHRH analogs.

Reality

They are different molecules with different pharmacology and, crucially, different regulatory status. Tesamorelin is GHRH(1-44) with a trans-3-hexenoyl modification, dosed daily, FDA-approved for HIV-lipodystrophy with a full Phase III evidence base. CJC-1295 has different amino acid substitutions and, in its DAC form, a maleimide linker that covalently binds serum albumin for week-long half-life; it was never FDA-approved and its sponsor's clinical program was abandoned after a safety signal. Shared class does not equal shared evidence.

Myth

Because tesamorelin is FDA-approved, it is safe and appropriate for anti-aging and longevity use.

Reality

FDA approval applies specifically to reduction of excess abdominal fat in HIV-infected patients with lipodystrophy. Off-label anti-aging and longevity use is legal under physician judgment but is not supported by the approval evidence base, is not covered by the approved safety monitoring framework, and involves the same theoretical GH/IGF-1 concerns — particularly around cancer risk — that attach to other GH secretagogues. The approved indication is narrow and the off-label leap is substantial.

Myth

Tesamorelin 'reprograms' your metabolism so the visceral fat loss is permanent.

Reality

The Phase III extension data shows visceral fat regresses when treatment stops — patients who discontinued tesamorelin regained VAT over subsequent months, while those who continued dosing maintained the reduction. Tesamorelin is a chronic treatment, not a one-time remodeling intervention. Patient counseling that implies 'do a cycle and you're done' misrepresents what the evidence actually supports.

Myth

Tesamorelin is not on the WADA list because it is FDA-approved.

Reality

Tesamorelin is explicitly prohibited under WADA S2 alongside other GHRH analogs, regardless of its FDA-approved status for HIV-lipodystrophy. An athlete with documented HIV-associated lipodystrophy might pursue a Therapeutic Use Exemption, but that is a case-by-case medical process, not an automatic exemption based on the drug being approved. Off-label sports use by any athlete subject to WADA code would be a prohibited substance violation.

Myth

Tesamorelin is safe in pregnancy because it just boosts natural GHRH.

Reality

Tesamorelin is contraindicated in pregnancy per the approved FDA label. 'Augments a natural pathway' is not a safety argument in pregnancy — the endocrine changes of pregnancy are complex, pharmacologic GH/IGF-1 elevation has not been characterized in reproductive-toxicology studies adequate to support use, and the contraindication reflects the absence of safety evidence rather than a formalistic caution.

Published Research

31 studies

Body composition, hepatic fat, metabolic, and safety outcomes of Tesamorelin, a GHRH analogue, in HIV-associated lipodystrophy: A meta-analysis of randomized controlled trials

Meta-AnalysisPMID: 41545261

Effects of Tesamorelin on Neurocognitive Impairment in Persons With HIV and Abdominal Obesity

Randomized Controlled TrialPMID: 39813152

Efficacy and safety of tesamorelin in people with HIV on integrase inhibitors

Randomized Controlled TrialPMID: 38905488

Growth Hormone Releasing Hormone Reduces Circulating Markers of Immune Activation in Parallel with Effects on Hepatic Immune Pathways in Individuals with HIV-infection and Nonalcoholic Fatty Liver Disease

Randomized Controlled TrialPMID: 33852720

Effects of tesamorelin on hepatic transcriptomic signatures in HIV-associated NAFLD

Randomized Controlled TrialPMID: 32701508

Clinical Predictors of Liver Fibrosis Presence and Progression in Human Immunodeficiency Virus-Associated Nonalcoholic Fatty Liver Disease

Randomized Controlled TrialPMID: 32270862

Tesamorelin

ReviewPMID: 31644039

Effects of tesamorelin on non-alcoholic fatty liver disease in HIV: a randomised, double-blind, multicentre trial

Clinical TrialPMID: 31611038

The Growth Hormone Releasing Hormone Analogue, Tesamorelin, Decreases Muscle Fat and Increases Muscle Area in Adults with HIV

Randomized Controlled TrialPMID: 31237318

Fibroblast growth factor 21 decreases after liver fat reduction via growth hormone augmentation

Randomized Controlled TrialPMID: 29031905

Safety and metabolic effects of tesamorelin, a growth hormone-releasing factor analogue, in patients with type 2 diabetes: A randomized, placebo-controlled trial

Randomized Controlled TrialPMID: 28617838

Predictors of Treatment Response to Tesamorelin, a Growth Hormone-Releasing Factor Analog, in HIV-Infected Patients with Excess Abdominal Fat

Randomized Controlled TrialPMID: 26457580

Population pharmacokinetic and pharmacodynamic analysis of tesamorelin in HIV-infected patients and healthy subjects

Phase I Clinical TrialPMID: 25895899

Population pharmacokinetic analysis of tesamorelin in HIV-infected patients and healthy subjects

Randomized Controlled TrialPMID: 25358450

Effect of tesamorelin on visceral fat and liver fat in HIV-infected patients with abdominal fat accumulation: a randomized clinical trial

Randomized Controlled TrialPMID: 25038357

The effects of tesamorelin on phosphocreatine recovery in obese subjects with reduced GH

Randomized Controlled TrialPMID: 24178787

Growth hormone-releasing hormone effects on brain γ-aminobutyric acid levels in mild cognitive impairment and healthy aging

Randomized Controlled TrialPMID: 23689947

Metabolic effects of a growth hormone-releasing factor in obese subjects with reduced growth hormone secretion: a randomized controlled trial

Randomized Controlled TrialPMID: 23015655

Effects of growth hormone–releasing hormone on cognitive function in adults with mild cognitive impairment and healthy older adults: results of a controlled trial

Randomized Controlled TrialPMID: 22869065

Reduction in visceral adiposity is associated with an improved metabolic profile in HIV-infected patients receiving tesamorelin

Randomized Controlled TrialPMID: 22495074

Tesamorelin: a growth hormone-releasing factor analogue for HIV-associated lipodystrophy

ReviewPMID: 22298602

Growth hormone and tesamorelin in the management of HIV-associated lipodystrophy

ReviewPMID: 22096409

Spotlight on tesamorelin in HIV-associated lipodystrophy

ReviewPMID: 22050344

Tesamorelin: a review of its use in the management of HIV-associated lipodystrophy

ReviewPMID: 21668043

Relationship of adiponectin to endogenous GH pulse secretion parameters in response to stimulation with a growth hormone releasing factor

Clinical TrialPMID: 21531600

Effects of tesamorelin on inflammatory markers in HIV patients with excess abdominal fat: relationship with visceral adipose reduction

Randomized Controlled TrialPMID: 21516030

Effects of tesamorelin, a growth hormone-releasing factor, in HIV-infected patients with abdominal fat accumulation: a randomized placebo-controlled trial with a safety extension

Randomized Controlled TrialPMID: 20101189

Tesamorelin, a human growth hormone releasing factor analogue

ReviewPMID: 19243281

Long-term safety and effects of tesamorelin, a growth hormone-releasing factor analogue, in HIV patients with abdominal fat accumulation

Randomized Controlled TrialPMID: 18690162

Metabolic effects of a growth hormone-releasing factor in patients with HIV

Randomized Controlled TrialPMID: 18057338

Drug evaluation: tesamorelin, a synthetic human growth hormone releasing factor

ReviewPMID: 17086939

Popular Stacks Including Tesamorelin

Quick Facts

Class
GHRH Analog
Tier
A
Evidence
Strong
Safety
Well-Studied
Updated
Apr 2026
Citations
31PubMed

Also known as

EgriftaEgrifta SVEgrifta WRTH9507

Tags

Growth HormoneBody CompositionFat LossFDA-Approved

Conditions Discussed

Evidence Score

Overall Confidence90%

Clinical Trials

View Clinical Trials

Links to ClinicalTrials.gov for reference. Listing does not imply endorsement.